PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Rhea-AI Summary

PolyPid (Nasdaq: PYPD) will report fourth quarter 2025 financial results and operational highlights before U.S. markets open on February 11, 2026, and will host a conference call and webcast at 8:30 AM ET.

The company said it expects to submit a New Drug Application (NDA) for D-PLEX100 in early 2026 after positive Phase 3 results; D-PLEX100 targets prevention of abdominal colorectal surgical site infections. Registration and webcast links are provided for investors.

Positive

• Positive Phase 3 results for D-PLEX100 reported
• NDA submission expected for D-PLEX100 in early 2026
• Scheduled Q4 2025 results release and investor webcast on Feb 11, 2026

Negative

• None.

News Market Reaction

-1.67%

1 alert

-1.67% News Effect

-$1M Valuation Impact

$80M Market Cap

0.0x Rel. Volume

On the day this news was published, PYPD declined 1.67%, reflecting a mild negative market reaction. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $80M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings date: February 11, 2026 Earnings call time: 8:30 AM Eastern Time Call registration lead time: 5 minutes +3 more

6 metrics

Earnings date February 11, 2026 Scheduled Q4 2025 financial results release

Earnings call time 8:30 AM Eastern Time Conference call to discuss Q4 2025 results

Call registration lead time 5 minutes Suggested minimum time before start of call

Phase of results Phase 3 Positive Phase 3 results for D-PLEX100

Expected NDA timing Early 2026 Planned New Drug Application submission for D-PLEX100

Quarter reported Fourth quarter 2025 Upcoming financial results being announced

Market Reality Check

Price: $4.58 Vol: Volume 22,481 vs 20-day a...

low vol

$4.58 Last Close

Volume Volume 22,481 vs 20-day average of 94,721 ahead of the earnings call date. low

Technical Price $4.80 is trading above the 200-day MA of $3.50 and within 5% of its 52-week high of $5.05.

Peers on Argus

PYPD gained 5.49% while key biotech peers were mixed: CAMP up 9.12%, KPTI up 5.2...

1 Down

PYPD gained 5.49% while key biotech peers were mixed: CAMP up 9.12%, KPTI up 5.22%, CUE and PDSB modestly positive, and VTVT down 1.25%, indicating stock-specific dynamics around the earnings date news.

Historical Context

5 past events · Latest: Dec 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 16	Board leadership change	Positive	-1.3%	Veteran MedTech leader appointed Chairman to support commercialization efforts.
Dec 03	Regulatory milestone	Positive	+4.8%	FDA pre‑NDA minutes supported rolling NDA submission for D‑PLEX100.
Nov 25	Investor outreach	Neutral	+1.7%	Participation in ROTH KOL event discussing D‑PLEX100’s clinical and economic case.
Nov 12	Earnings and update	Neutral	-0.3%	Q3 2025 loss and cash runway outlook alongside NDA timing update.
Nov 06	Clinical recognition	Positive	+0.3%	D‑PLEX100 won therapeutic award with strong Phase 3 efficacy data.

Pattern Detected

Shares have tended to react positively to regulatory and clinical milestones, while management changes and results updates have seen more muted or negative follow-through.

Recent Company History

Over the past few months, PolyPid has highlighted progress toward an NDA for D-PLEX100, including positive FDA pre‑NDA minutes on Dec 3, 2025 and a Q3 2025 update on Nov 12, 2025. The lead asset also received a therapeutics award on Nov 6, 2025, and the company strengthened governance with a new Board chair on Dec 11, 2025. Today’s announcement of the Feb 11, 2026 Q4 2025 results date fits into this cadence of advancing D-PLEX100 toward an expected early 2026 NDA submission.

Market Pulse Summary

This announcement sets February 11, 2026 as the next checkpoint for Q4 2025 results and operational ...

Analysis

This announcement sets February 11, 2026 as the next checkpoint for Q4 2025 results and operational updates, against a backdrop of positive Phase 3 data and an expected early 2026 NDA for D‑PLEX100. Investors may focus on cash trends, development timelines, and commercialization plans for preventing colorectal surgical site infections. Recent history shows steady regulatory and clinical progress, so clarity on execution and funding at the call could be particularly important.

Key Terms

new drug application (nda), surgical site infections, active pharmaceutical ingredients (apis), phase 3, +2 more

6 terms

new drug application (nda) regulatory

"Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX100..."

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

surgical site infections medical

"for the prevention of abdominal colorectal surgical site infections, is expected..."

Surgical site infections are infections that occur where a surgical cut was made, caused by bacteria or other germs entering the wound during or after an operation. They matter to investors because higher infection rates can increase hospital costs, lead to regulatory action, product recalls, lawsuits, and damaged reputations—similar to how a manufacturing defect forces costly recalls and repairs—so they affect revenue, margins, and risk for companies in healthcare and medical products.

active pharmaceutical ingredients (apis) medical

"technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery..."

Active pharmaceutical ingredients (APIs) are the chemical or biological substances in a medicine that produce the intended therapeutic effect — think of them as the engine inside a car that makes it run. Investors care because API supply, quality, cost, and intellectual property control determine a drug maker’s ability to sell medicines, meet regulatory requirements, and protect profit margins; disruptions or shortages can quickly affect revenue and stock value.

phase 3 medical

"Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX100..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

oncology medical

"In addition, the Company has an innovative pipeline in oncology, obesity and diabetes."

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

diabetes medical

"innovative pipeline in oncology, obesity and diabetes."

Diabetes is a chronic health condition where the body can’t properly regulate blood sugar, like a thermostat that can’t keep temperature steady. It matters to investors because it drives long-term demand for medicines, medical devices, testing supplies and health services, influences healthcare spending and insurance costs, and affects workforce productivity — all of which can meaningfully influence company revenues and sector performance.

AI-generated analysis. Not financial advice.

PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	February 11, 2026
Time:	8:30 AM Eastern Time
Conference Call:	https://register-conf.media-server.com/register/BI793c5305462d49cea4ba91529d2636bf
Webcast:	https://edge.media-server.com/mmc/p/izp7gdk6

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid’s lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the NDA submission of D-PLEX₁₀₀ and the timing thereof. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

FAQ

When will PolyPid (PYPD) release Q4 2025 financial results and hold the earnings call?

PolyPid will release Q4 2025 results before U.S. market open on February 11, 2026. According to the company, a conference call and webcast will follow at 8:30 AM ET to discuss results and operational highlights.

What is the timing for PolyPid's NDA submission for D-PLEX100 (PYPD)?

PolyPid expects to submit an NDA for D-PLEX100 in early 2026. According to the company, this follows reported positive Phase 3 results for prevention of abdominal colorectal surgical site infections.

How can investors access PolyPid’s (PYPD) February 11, 2026 webcast and conference call?

Investors can register for the conference call and access the live webcast via the provided registration and media-server links. According to the company, registering at least 5 minutes before the 8:30 AM ET start is recommended.

What clinical milestone did PolyPid (PYPD) report for D-PLEX100?

PolyPid reported positive Phase 3 results for D-PLEX100. According to the company, these results support an NDA submission aimed at preventing abdominal colorectal surgical site infections.

Will PolyPid (PYPD) discuss operational updates during the February 11, 2026 call?

Yes, PolyPid will provide operational highlights alongside financial results on the Feb 11 call at 8:30 AM ET. According to the company, management will discuss business operations and take questions during the webcast and call.